CN108472305A - 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物 - Google Patents

使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物 Download PDF

Info

Publication number
CN108472305A
CN108472305A CN201780006641.XA CN201780006641A CN108472305A CN 108472305 A CN108472305 A CN 108472305A CN 201780006641 A CN201780006641 A CN 201780006641A CN 108472305 A CN108472305 A CN 108472305A
Authority
CN
China
Prior art keywords
disease
sialyllactose
composition
agent
mentioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780006641.XA
Other languages
English (en)
Chinese (zh)
Inventor
康丞雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Benebiosis Co Ltd
Original Assignee
Benebiosis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benebiosis Co Ltd filed Critical Benebiosis Co Ltd
Priority to CN202511095689.5A priority Critical patent/CN120661527A/zh
Priority to CN202511095571.2A priority patent/CN120643579A/zh
Publication of CN108472305A publication Critical patent/CN108472305A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04Disaccharides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332Promoters of weight control and weight loss

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
CN201780006641.XA 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物 Pending CN108472305A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202511095689.5A CN120661527A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN202511095571.2A CN120643579A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160004383 2016-01-13
KR10-2016-0004383 2016-01-13
PCT/KR2017/000505 WO2017123066A1 (ko) 2016-01-13 2017-01-13 Pgc-1알파의 발현을 증가시키는 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202511095689.5A Division CN120661527A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN202511095571.2A Division CN120643579A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Publications (1)

Publication Number Publication Date
CN108472305A true CN108472305A (zh) 2018-08-31

Family

ID=59311711

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202511095689.5A Pending CN120661527A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN201780006641.XA Pending CN108472305A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN202511095571.2A Pending CN120643579A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202511095689.5A Pending CN120661527A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511095571.2A Pending CN120643579A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Country Status (12)

Country Link
US (1) US20190030053A1 (enExample)
EP (2) EP3845233A1 (enExample)
JP (3) JP7125348B2 (enExample)
KR (3) KR20210079376A (enExample)
CN (3) CN120661527A (enExample)
CA (2) CA3010338C (enExample)
ES (1) ES2946945T3 (enExample)
HK (1) HK1257689A1 (enExample)
MX (2) MX389553B (enExample)
MY (1) MY197561A (enExample)
SG (1) SG11201805791RA (enExample)
WO (1) WO2017123066A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3498282A1 (en) 2017-12-12 2019-06-19 Rheinische Friedrich-Wilhelms-Universität Bonn 6'-sialyllactose for use in the treatment of hearing loss
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
CN113825516B (zh) * 2019-03-05 2025-03-11 格礼卡姆股份公司 用于增强执行功能的人乳寡糖
CN113518622A (zh) * 2019-03-05 2021-10-19 雀巢产品有限公司 用于增强执行功能的营养组合物
JP2021038147A (ja) * 2019-08-30 2021-03-11 国立大学法人 鹿児島大学 ミトコンドリア生合成促進剤
KR102186761B1 (ko) * 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
GB202114190D0 (en) * 2021-10-04 2021-11-17 Mjn Us Holdings Llc Compositions for preventing and/or treating demyelination
AU2024281828A1 (en) * 2023-06-02 2025-12-04 Zydus Lifesciences Limited Treatment for amyotrophic lateral sclerosis (als)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112134A (zh) * 2008-08-01 2011-06-29 Benebiosis株式会社 高脂血症,脂肪肝或肥胖的预防或治疗用组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
JPH07258093A (ja) * 1994-03-23 1995-10-09 Morinaga Milk Ind Co Ltd 神経成長因子様剤
KR101112051B1 (ko) * 2009-04-09 2012-02-14 주식회사 베네비오 비후성 반흔 또는 켈로이드 예방 또는 치료용 조성물
KR20110092602A (ko) * 2010-02-09 2011-08-18 주식회사 베네비오 플라스미노겐 활성 억제인자-1의 억제제
EP2658547A1 (en) * 2010-12-31 2013-11-06 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
WO2014043358A1 (en) * 2012-09-14 2014-03-20 Robert Bosch Gmbh Device testing using acoustic port obstruction
CN104955344A (zh) 2012-12-18 2015-09-30 雅培制药有限公司 包含神经保护膳食寡糖的营养组合物
CN104822279B (zh) 2012-12-18 2020-09-11 雅培制药有限公司 缓减应激症状的人乳寡糖
DE102013208103A1 (de) 2013-05-03 2014-11-06 Siemens Aktiengesellschaft Röntgenquelle und bildgebendes System
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112134A (zh) * 2008-08-01 2011-06-29 Benebiosis株式会社 高脂血症,脂肪肝或肥胖的预防或治疗用组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUMIHIKO SAKAI ET AL.: "Effects of Feeding Sialyllactose and Galactosylated N-Acetylneuraminic Acid on Swimming Learning Ability and Brain Lipid Composition in Adult Rats", 《J.APPL.GLYCOSCI.》 *
TAKAHIRO YONEKAWA 等: "Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice", 《BRAIN》 *

Also Published As

Publication number Publication date
KR20230107718A (ko) 2023-07-17
KR102771814B1 (ko) 2025-02-26
EP3403655C0 (en) 2023-06-07
SG11201805791RA (en) 2018-08-30
CA3203927A1 (en) 2017-07-20
MX389553B (es) 2025-03-20
HK1257689A1 (zh) 2019-10-25
CA3010338A1 (en) 2017-07-20
KR20210079376A (ko) 2021-06-29
MY197561A (en) 2023-06-23
WO2017123066A1 (ko) 2017-07-20
RU2018128408A (ru) 2020-02-13
CN120661527A (zh) 2025-09-19
ES2946945T3 (es) 2023-07-28
CN120643579A (zh) 2025-09-16
EP3845233A1 (en) 2021-07-07
EP3403655A4 (en) 2019-08-07
EP3403655B1 (en) 2023-06-07
JP7467543B2 (ja) 2024-04-15
RU2018128408A3 (enExample) 2020-02-13
MX2022000945A (es) 2022-02-14
CA3010338C (en) 2023-08-22
JP2022166164A (ja) 2022-11-01
MX2018008671A (es) 2019-02-13
JP2024081767A (ja) 2024-06-18
EP3403655A1 (en) 2018-11-21
US20190030053A1 (en) 2019-01-31
JP2019502718A (ja) 2019-01-31
KR20180099885A (ko) 2018-09-05
JP7125348B2 (ja) 2022-08-24

Similar Documents

Publication Publication Date Title
JP7467543B2 (ja) PGC-1αの発現を増加させる組成物
CN103002868B (zh) 作为活性溶脂成分的氨基甲酸环己酯化合物
CN104902962B (zh) 西番莲种子提取物及含有其的化妆品、药物、皮肤病学和营养学组合物
JP7214268B2 (ja) 皮膚用組成物
US20110085996A1 (en) External preparation composition for skin comprising ginseng flower or ginseng seed extracts
EP3277254B1 (en) Topical cosmetic treatment of skin and scalp and corresponding active ingredient based on an extract of apium graveolens
WO2009124971A2 (en) Novel compositions and their use
KR20150126621A (ko) 피부 회춘을 위한 펩타이드 및 이것을 사용하는 방법
EP2914349B1 (en) Combination of plant extracts, cosmetic ingredient and composition containing it and topical cosmetic use thereof
US20130058878A1 (en) Cosmetic Use Of Geranylgeranyl-2-Propanol
CN105899186A (zh) 含有可用于美容、皮肤或美容保健合成物的蔗糖酯活性成分的植物萃取物
TW202529774A (zh) 用於改善皮膚血液循環的組合物
KR101430636B1 (ko) 진세노사이드 Rh2 및 진세노사이드 Rg3를 함유하는 기능성 화장료 조성물
KR20170001649A (ko) 혼합 생약재 추출물을 함유하는 주름개선 및 보습용 조성물
CN105636653A (zh) 圭亚那塔皮漆木提取物的化妆品或皮肤病学用途
RU2814560C2 (ru) КОМПОЗИЦИЯ ДЛЯ ПОВЫШЕНИЯ ЭКСПРЕССИИ PGC-1α
KR101460672B1 (ko) 참바늘버섯 자실체 추출물을 함유하는 모발손상 방지용 조성물
JP2025166578A (ja) Hoxa9発現促進剤
JP2025178716A (ja) Hoxa9発現促進剤
KR101460670B1 (ko) 참바늘버섯 자실체 추출물을 함유하는 여드름 개선, 예방 또는 치료용 조성물
CN118043048A (zh) M2或m2样巨噬细胞的诱导或激活剂、m2或m2样巨噬细胞的诱导或激活方法、用于预防和/或改善真皮的色素沉积的组合物、以及预防和/或改善真皮的色素沉积的方法
TW201924656A (zh) 用於調節黑色素生成的方法及組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257689

Country of ref document: HK